Eligibility for intravenous thrombolysis in acute ischemic stroke patients presenting in the 4.5–9 h window
- 1 February 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Neuroradiology
- Vol. 62 (6), 733-739
- https://doi.org/10.1007/s00234-020-02375-2
Abstract
Purpose Recent randomized-controlled clinical trials have provided preliminary evidence for expanding the time window of intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) patients by applying certain neuroimaging criteria. We prospectively assessed the potential eligibility for IVT in the extended time window (4.5–9 h) among consecutive AIS patients treated in a comprehensive stroke center during a nine-month period. Methods Potential eligibility for IVT in the extended time window was evaluated by using inclusion criteria from the EXTEND trial. All patients were underwent baseline emergent neurovascular imaging using either computed tomography angiography/computed tomography perfusion (CTA/CTP) or magnetic resonance angiography/magnetic resonance perfusion (MRA/MRP). Images were post processed by the automated software RAPID. Results Our study population consisted of 317 AIS patients, and, among them, 31 (9.8 %) patients were presented in the time window of 4.5–9 h. Seven patients (2.2 %) fulfilled the EXTEND neuroimaging criteria. Four patients (1.3 %) were treated with IVT because they fulfilled both clinical and neuroimaging EXTEND criteria. Patients eligible for EXTEND neuroimaging criteria had no ischemic core lesion, whereas the mean volume of critical hypoperfusion was relatively small (17.0 ± 11.8 ml). There was no hemorrhagic complication in any of the patients treated with IVT. The median mRS score at three months was 0 (range: 0–3) among patients who were eligible for EXTEND neuroimaging criteria. Conclusion Our everyday clinical practice experience suggests 9.8 % of consecutive AIS patients present in the 4.5–9 h window and 2.2 % adhere to EXTEND neuroimaging eligibility criteria for IVT. Only 1.3% of AIS is eligible for IVT according to EXTEND neuroimaging and clinical eligibility criteria.This publication has 18 references indexed in Scilit:
- 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke AssociationStroke, 2018
- Intravenous thrombolysis for acute ischemic stroke: a bridge between two centuriesExpert Review of Neurotherapeutics, 2017
- Admission hyperglycemia and outcomes in large vessel occlusion strokes treated with mechanical thrombectomyJournal of NeuroInterventional Surgery, 2017
- Desmoteplase 3 to 9 Hours After Major Artery Occlusion StrokeStroke, 2016
- Eligibility for mechanical thrombectomy in acute ischemic stroke: A phase IV multi-center screening log registryJournal of the Neurological Sciences, 2016
- Safety and efficacy of desmoteplase given 3–9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trialThe Lancet Neurology, 2015
- Imaging Selection in Ischemic Stroke: Feasibility of Automated CT-Perfusion AnalysisInternational Journal of Stroke, 2014
- Understanding the reasons behind the low utilisation of thrombolysis in strokeAustralasian Medical Journal, 2013
- Tissue Plasminogen Activator for Acute Ischemic StrokeThe New England Journal of Medicine, 1995
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993